Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBMDrug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target therapeutic dosesCompany plans to engage the U.S.

Cortice Bioscience的战略许可证与正在进行的潜在关键的伯柔比星计划具有高度的协同作用，并证明了进一步致力于改变GBMDrug候选药物TPI 287的治疗模式，TPI 287被授予孤儿称号，并在迄今为止的350多名患者中进行了研究，包括作为单一疗法的临床试验以及与贝伐单抗联合使用，证明了在目标治疗剂量下令人鼓舞的临床疗效和安全性。公司计划与美国合作。

FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBMLeveraging the significant clinical infrastructure and deep relationships established with the Neuro-Oncology community to expedite development of TPI 287Company launches new corporate brand and website to more closely align with its unwavering commitment to addressing the most aggressive type of brain cancer, GBM, with an average survival of only 14 to 16 months after diagnosis and no cureCompany to host live video webcast to discuss the transaction today, July 30 th at 8:30 AM ETHOUSTON, TX / ACCESSWIRE / July 30, 2024 / CNS Pharmaceuticals, Inc.

FDA将寻求指导，将TPI 287推进复发性GBM的潜在注册研究，包括重要的临床基础设施和与神经肿瘤学界建立的深入关系，以加快TPI 287的发展。公司推出了新的公司品牌和网站，以更紧密地配合其坚定的承诺，以解决最具侵略性的脑癌类型GBM，诊断后平均生存期仅为14至16个月，并且没有治愈公司在今天，7月30日上午8:30在德克萨斯州埃索斯顿/ACCESSWIRE/2024年7月30日/CNS Pharmaceuticals，Inc。

(NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has entered into an exclusive license agreement with Cortice Biosciences, Inc. ('Cortice').

（纳斯达克：CNSP）（“CNS”或“公司”）是一家专门开发针对大脑和中枢神经系统原发性和转移性癌症的新型治疗方法的生物制药公司，今天宣布，它已与Cortice Biosciences，Inc.（“Cortice”）签订了独家许可协议。

The Company will host a live webcast presentation to discuss the transaction on Tuesday, July 30, 2024 at 8:30 AM ET (details below). Additionally, CNS announced the launch of its new corporate branding and website, cnspharma.com.Under the terms of the Agreement, CNS Pharmaceuticals has obtained an exclusive license and the intellectual proper.

该公司将于2024年7月30日（星期二）美国东部时间上午8:30（详情如下）主持一场在线直播，讨论该交易。此外，CNS宣布推出其新的企业品牌和网站cnspharma.com。根据协议条款，CNS Pharmaceuticals已获得独家许可和知识产权。